The highly lucrative Singaporean medical market, which is expected to reach $49 billion by 2029, is where Neurophet hopes to make its entry.
South Korean health tech company Neurophet has received certification from Singapore’s Health Sciences Authority for its AI-enabled degenerative brain disease diagnosis assistant software.
In order to detect brain atrophy and white matter degeneration, which are signs of neurodegenerative diseases like Alzheimer’s disease and vascular dementia, the company’s flagship software, Neurophet Aqua, analyses brain MRIs using artificial intelligence.
The business asserts that its product has a 0% analysis failure rate and can segment and analyse brain images in five minutes.
The highly lucrative Singaporean medical market, which is expected to reach $49 billion by 2029, is where Neurophet hopes to make its entry.
The Neurophet Scale PET, developed by the company, was the first product on the market to quantitatively analyse biomarkers for Alzheimer’s disease by fusing brain PET and MRI images. Late last year, it also received HSA approval for this.
By partnering with the Dementia Research Center at the Lee Kong Chian School of Medicine at Nanyang Technological University in Singapore to conduct multidisciplinary degenerative brain disease research that will validate its AI software offerings, the company is working extra hard to further penetrate the greater Southeast Asian market.
To increase access to Neurophet Aqua in the Japanese market, the company teamed up with medical device distributor Clairvo Technologies in December.
A medical software company called NEUROPHET creates neuro-navigation solutions that help clinicians treat patients more effectively and give better brain treatments by utilising cutting-edge neuroscience and AI technologies. In 2016, NEUROPHET was established.
It is creating neuro-engineering simulation software with a focus on electrical brain stimulation for medical professionals and academics (EBS). Users can simulate and examine the potential effects of EBS on the various treatment parameters in a clinical setting, as well as create an individual 3D brain model using MRI. It aids in the creation of 3D brain models for each patient completely automatically.